top of page

Boehringer Ingelheim's Spiriva Respimat available in the US

Boehringer Ingelheim’s Spiriva Respimat is now available for the treatment of asthma by prescription in US pharmacies. The US Food and Drug Administration (FDA) approved a once-daily dose of 2.5 µg for the long-term maintenance treatment of asthma in people ages 12 and older.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page